"Researchers 'Encouraged' By early Data From Universal Flu Vaccine Study" - Marley Ghizzone
Researchers from the Icahn School of Medicine at Mount Sinai were “encouraged” by the interim results from a phase one study of a novel influenza vaccine approach they hope will one day protect patients from both seasonal and pandemic influenza. “We are very encouraged that the preliminary data are compelling in terms of inducing a protective and long-lasting immune response in humans,” said Peter Palese, PhD, professor of microbiology, medicine, and infectious disease at the Icahn School of Medicine at Mount Sinai. According to Florian Krammer, PhD, professor of microbiology at the Icahn School of Medicine at Mount Sinai, “We are currently in phase one trials; it would take phase two and then phase three trials — of a yet unspecified design — to bring this to the market.”
— Peter Palese, PhD, Professor, Microbiology, Medicine, Infectious Disease, Chair, Microbiology, Icahn School of Medicine at Mount Sinai
— Florian Krammer, PhD, Professor, Microbiology, Icahn School of Medicine at Mount Sinai
Additional coverage: Clinical Lab Manager; Precision Vaccinations
